Research trends and hotspots in the immune microenvironment related to hepatocellular carcinoma: A bibliometric and visualization study

被引:0
作者
Zhang, Da-Ya [1 ]
Bai, Fei-Hu [2 ,3 ]
机构
[1] Hainan Med Univ, Dept Grad Sch, Haikou 571199, Hainan, Peoples R China
[2] Hainan Med Univ, Dept Gastroenterol, Affiliated Hosp 2, 368 Yehai Ave, Haikou 570216, Hainan, Peoples R China
[3] Gastroenterol Clin Med Ctr Hainan Prov, Dept Gastroenterol, Haikou 570216, Hainan, Peoples R China
基金
芬兰科学院;
关键词
Immune microenvironment; Hepatocellular carcinoma; Bibliometrics; VOSviewer; Citespace; Frontiers;
D O I
10.4251/wjgo.v16.i7.3321
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND The immune microenvironment (IME) in hepatocellular carcinoma (HCC) plays a pivotal role in determining patient outcomes and responses to treatment. This area is witnessing rapid growth in research interest. However, there is a lack of comprehensive bibliometric analyses that dissect trends and potential focal points in this field. AIM To explore the evolution of research on the IME in HCC from January 1, 2004, to December 31, 2023, using bibliometric methodologies. METHODS English articles and reviews concerning the IME of HCC were retrieved from the Web of Science Core Collection with a search date of December 31, 2023. The R package Bibliometrix was employed to compute basic bibliometric characteristics, illustrate collaborations among countries and authors, and create a three-field diagram illustrating the connections between authors, affiliations, and keywords. Analyses of country and institutional co-authorship, as well as keyword co-occurrence, were conducted using VOSviewer. Additionally, CiteSpace was utilized for the cite burst analysis of keywords and cited literature. RESULTS The study encompassed 3125 documents in the research areas related to HCC of IME, revealing a substantial and continuous increase in the annual publication trend over time. China and Fudan University emerged as leading contributors, with 2103 and 165 publications, respectively. Frontiers in immunology was the most prolific journal in this domain. Among the top ten researchers in the field, eight are based in China. Key research terms identified include tumour microenvironment, expression, immunotherapy, and prognosis. CONCLUSION The relationship between HCC and IME is receiving increasing attention, and related research is in a highly developed stage. Key focus areas, including IME and immune checkpoint inhibitors, immunotherapy are poised to be central to future research endeavors, offering promising pathways for further exploration.
引用
收藏
页数:11
相关论文
共 30 条
  • [1] A human liver cell atlas reveals heterogeneity and epithelial progenitors
    Aizarani, Nadim
    Saviano, Antonio
    Sagar
    Mailly, Laurent
    Durand, Sarah
    Herman, Josip S.
    Pessaux, Patrick
    Baumert, Thomas F.
    Gruen, Dominic
    [J]. NATURE, 2019, 572 (7768) : 199 - 204
  • [2] The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
    Donne, Romain
    Lujambio, Amaia
    [J]. HEPATOLOGY, 2023, 77 (05) : 1773 - 1796
  • [3] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H., III
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    dela Cruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    Dastani, Homa B.
    Melero, Ignacio
    [J]. LANCET, 2017, 389 (10088) : 2492 - 2502
  • [4] Hepatocellular carcinoma
    Forner, Alejandro
    Reig, Maria
    Bruix, Jordi
    [J]. LANCET, 2018, 391 (10127) : 1301 - 1314
  • [5] Hallmarks of Cancer: New Dimensions
    Hanahan, Douglas
    [J]. CANCER DISCOVERY, 2022, 12 (01) : 31 - 46
  • [6] Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
    Kanwal, Fasiha
    Singal, Amit G.
    [J]. GASTROENTEROLOGY, 2019, 157 (01) : 54 - 64
  • [7] Scientific Productivity in Rheumatology Among Countries of the Organisation for Economic Co-operation and Development and Its Correlation to National Economic Indicators
    Lerman, Tsahi T.
    Reitblat, Olga
    Reitblat, Tatiana
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 (03) : 92 - 96
  • [8] CXCR2 inhibition enables NASH-HCC immunotherapy
    Leslie, Jack
    Mackey, John B. G.
    Jamieson, Thomas
    Ramon-Gil, Erik
    Drake, Thomas M.
    Fercoq, Frederic
    Clark, William
    Gilroy, Kathryn
    Hedley, Ann
    Nixon, Colin
    Luli, Saimir
    Laszczewska, Maja
    Pinyol, Roser
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Haber, Philipp K.
    Andreu-Oller, Carmen
    Rahbari, Mohammad
    Fan, Chaofan
    Pfister, Dominik
    Raman, Shreya
    Wilson, Niall
    Muller, Miryam
    Collins, Amy
    Geh, Daniel
    Fuller, Andrew
    McDonald, David
    Hulme, Gillian
    Filby, Andrew
    Cortes-Lavaud, Xabier
    Mohamed, Noha-Ehssan
    Ford, Catriona A.
    Iraolagoitia, Ximena L. Raffo
    McFarlane, Amanda J.
    McCain, Misti, V
    Ridgway, Rachel A.
    Roberts, Edward W.
    Barry, Simon T.
    Graham, Gerard J.
    Heikenwalder, Mathias
    Reeves, Helen L.
    Llovet, Josep M.
    Carlin, Leo M.
    Bird, Thomas G.
    Sansom, Owen J.
    Mann, Derek A.
    [J]. GUT, 2022, 71 (10) : 2093 - 2106
  • [9] Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study
    Liu, Yao-Ge
    Jiang, Shi-Tao
    Zhang, Lei
    Zheng, Han
    Zhang, Ting
    Zhang, Jun-Wei
    Zhao, Hai-Tao
    Sang, Xin-Ting
    Xu, Yi-Yao
    Lu, Xin
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [10] Immunotherapies for hepatocellular carcinoma
    Llovet, Josep M.
    Castet, Florian
    Heikenwalder, Mathias
    Maini, Mala K.
    Mazzaferro, Vincenzo
    Pinato, David J.
    Pikarsky, Eli
    Zhu, Andrew X.
    Finn, Richard S.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (03) : 151 - 172